The DOI matches its Crossref record.
Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection in Japan: Projection to Other Countries in the Foreseeable Future
Abstract
During the turmoil after the end of World War II some 50 years ago, in Japan intravenous methamphetamine was widespread and penetrated the young generation aged 15-25 years and remunerated blood donors. The vicious cycle gave an enormous thrust to the spread of hepatitis C virus (HCV) infection among drug users and blood donors. Their HCV infection was transmitted to the general population through transfusions, folk medicine involving the breaking of the integument and tattooing. Indiscreet and widespread treatment with intravenous injection using contaminated syringes and needles at that time accelerated the transmission of HCV further. An overall result was the outbreak of HCV infection in restricted subpopulations in Japan, which inevitably involved the general population. Abrogation of paid blood donation in 1968, the exclusion of blood units contaminated with hepatitis B virus (HBV) in 1973 and that of HCV since November 1989 (by the second generation tests after February 1992) decreased the risk of posttransfusion hepatitis from >50% in the 1960s to infinitely close to zero at present. Now the incidence of HCV infection in Japan is decreased to 1.8-3.5/100,000 person-years. Mother-to-baby transmission of HBV has been prevented since 1986 by a combined passive and active immunoprophylaxis of the babies at risk with hepatitis B immune globulin and vaccine. What we see today in Japan, however, is an ever-increasing incidence of hepatocellular carcinoma (HCC) that has reached almost 40/100,000 population, with males >50 years accounting for the great majority. Of the HCC cases in Japan, approximately 16% is caused by HBV infection and approximately 80% by HCV infection. The growing incidence of HCC is expected to reach a plateau around the year 2015, and then to start to decrease. The ordeal we have gone through, with special reference to the increasing incidence of HCV-associated HCC, is expected elsewhere in the world with a current profile of age-specific HCV infection like ours a few decades back. For worse or better (probably in this order), Japan is a country far advanced as regards the HCC associated with HCV infection. Our long-term experience related in detail here is hoped to help plan strategies to contain HCV infection and cope with its long-term sequelae in many other countries worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Global patterns of cancer incidence and mortality rates and trends
Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0437 · Cited by 2,778
Primary liver cancer: Worldwide incidence and trends
Bosch, F. X., Ribes, J., Díaz, M., & Cléries, R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.011 · Cited by 2,477
Solid Cancer Incidence in Atomic Bomb Survivors: 1958–1998
Preston, D. L., Ron, E., Tokuoka, S., Funamoto, S., Nishi, N., Soda, M., Mabuchi, K., & Kodama, K. (2007) · Radiation Research · doi:10.1667/rr0763.1 · Cited by 1,753
Epidemiology of Hepatocellular Carcinoma
Bosch, F. X., Ribes, J., Cléries, R., & Díaz, M. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.12.009 · Cited by 1,131
Epidemiology of Hepatocellular Carcinoma: Consider the Population
Mittal, S., & El-Serag, H. B. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182872f29 · Cited by 1,076
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Epidemiology and natural history of HCV infection
Hajarizadeh, B., Grebely, J., & Dore, G. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.107 · Cited by 994
Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis
Rowe, J., Ghouri, Y., & Mian, I. (2017) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_9_16 · Cited by 719
The changing pattern of epidemiology in hepatocellular carcinoma
Nordenstedt, H., White, D. L., & El-Serag, H. B. (2010) · Digestive and Liver Disease · doi:10.1016/s1590-8658(10)60507-5 · Cited by 535
Epidemiology of Hepatitis B and C Viruses: A Global Overview
Te, H. S., & Jensen, D. M. (2010) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.11.009 · Cited by 482
Hepatocellular Carcinoma – Epidemiological Trends and Risk Factors
Schütte, K., Bornschein, J., & Malfertheiner, P. (2009) · Digestive Diseases · doi:10.1159/000218339 · Cited by 441
Epidemiology of Hepatocellular Carcinoma
El-Serag, H. B. (2001) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70155-0 · Cited by 327
Hepatocellular carcinoma: Recent trends in Japan
Kiyosawa, K., Umemura, T., Ichijo, T., Matsumoto, A., Yoshizawa, K., Gad, A., & Tanaka, E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.012 · Cited by 308
Epidemiology of Hepatocellular Carcinoma
Lafaro, K. J., Demirjian, A. N., & Pawlik, T. M. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.09.001 · Cited by 303
Hepatocellular carcinoma and hepatitis C in the United States
El-Serag, H. B. (2002) · Hepatology · doi:10.1002/hep.1840360710 · Cited by 291
Cabrera, R. (2012) · Hepatic Medicine: Evidence and Research · doi:10.2147/hmer.s16316 · Cited by 274
Ikeda, N., Inoue, M., Iso, H., Ikeda, S., Satoh, T., Noda, M., Mizoue, T., Imano, H., Saito, E., Katanoda, K., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001160 · Cited by 240
“We also included infection by several agents—hepatitis B virus, hepatitis C virus, the bacterium Helicobacter pylori, human papillomavirus, and human T-lymphotropic virus type 1 (HTLV1)—because they are important risk factors for cancer deaths in Japan [26,27].”
BackgroundOkamura, T., Tanaka, H., Miyamatsu, N., Hayakawa, T., Kadowaki, T., Kita, Y., Nakamura, Y., Okayama, A., & Ueshima, H. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.01.024 · Cited by 172
Tateishi, R., Okanoue, T., Fujiwara, N., Okita, K., Kiyosawa, K., Omata, M., Kumada, H., Hayashi, N., & Koike, K. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-014-0973-8 · Cited by 170
Tanaka, H., Tsukuma, H., Yamano, H., Oshima, A., & Shibata, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.20507 · Cited by 57
Metadata
- Authors
- Yoshizawa, H.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 62
- Issue
- Suppl. 1
- Pages
- 8-17
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2045934614
- Cited by
- 229
- References
- 0
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.